Toward personalized cancer nanomedicine-past, present, and future

Integrative Biology (United Kingdom)

Volumn 5, Issue 1, 2013, Pages 48-65

  Stegh, Alexander H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEFITINIB; IMATINIB; LAPATINIB; METAL NANOPARTICLE; NANOCONJUGATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAS PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTOME; TRASTUZUMAB; VEMURAFENIB; VISMODEGIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CELL LINEAGE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DISEASE COURSE; DNA DAMAGE; GENE FUNCTION; GENOME; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; MULTIPLE MYELOMA; MYELOFIBROSIS; MYELOMA; NANOMEDICINE; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; TUMOR GENE; UVEA MELANOMA;

EID: 84871820504     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c2ib20104f     Document Type: Review

References (149)

1. E. L. Kwak et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 2010 363 18 1693 1703
2. P. B. Chapman et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011 364 26 2507 2516
3. M. D. Pegram et al., Trastuzumab and chemotherapeutics: drug interactions and synergies Semin. Oncol. 2000 27 6 Suppl 11 21 25
4. B. J. Druker et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 2001 344 14 1031 1037
5. T. J. Lynch et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2004 350 21 2129 2139
6. J. G. Paez et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500
7. W. Pao et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U. S. A. 2004 101 36 13306 13311
8. H. Hurwitz et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 2004 350 23 2335 2342
9. A. Sandler et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 2006 355 24 2542 2550
10. J. C. Yang et al., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 2003 349 5 427 434
11. J. J. Vredenburgh et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J. Clin. Oncol. 2007 25 30 4722 4729
12. J. J. Vredenburgh et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin. Cancer Res. 2007 13 4 1253 1259
13. H. Davies et al., Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954
14. J. Tsai et al., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 2008 105 8 3041 3046
15. E. W. Joseph et al., The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc. Natl. Acad. Sci. U. S. A. 2010 107 33 14903 14908
16. S. Verstovsek et al., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N. Engl. J. Med. 2010 363 12 1117 1127
17. R. Kurzrock et al., Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J. Clin. Oncol. 2011 29 19 2660 2666
18. K. D. Courtney et al., The PI3K pathway as drug target in human cancer J. Clin. Oncol. 2010 28 6 1075 1083
19. D. D. Von Hoff et al., Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N. Engl. J. Med. 2009 361 12 1164 1172
20. P. C. Fong et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 2009 361 2 123 134
21. L. L. Rubin F. J. de Sauvage Targeting the Hedgehog pathway in cancer Nat. Rev. Drug Discovery 2006 5 12 1026 1033
22. H. Farmer et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 7035 917 921
23. H. E. Bryant et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005 434 7035 913 917
24. C. D. Van Raamsdonk et al., Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi Nature 2009 457 7229 599 602
25. X. S. Puente et al., Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 2011 475 7354 101 105
26. M. A. Chapman et al., Initial genome sequencing and analysis of multiple myeloma Nature 2011 471 7339 467 472
27. G. L. Dalgliesh et al., Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 2010 463 7279 360 363
28. S. Jones et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 2010 330 6001 228 231
29. M. Albert K. Helin Histone methyltransferases in cancer Semin. Cell Dev. Biol. 2009 21 2 209 220
30. T. J. Ley et al., DNMT3A mutations in acute myeloid leukemia N. Engl. J. Med. 2010 363 25 2424 2433
31. H. Yan et al., IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 2009 360 8 765 773
32. M. E. Figueroa et al., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia Cancer Cell 2010 17 1 13 27
33. F. Delhommeau et al., Mutation in TET2 in myeloid cancers N. Engl. J. Med. 2009 360 22 2289 2301
34. The Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 2008, 455 (7216), 1061 1068
35. The Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma, Nature, 2011, 474 (7353), 609 615
36. L. Chin J. W. Gray Translating insights from the cancer genome into clinical practice Nature 2008 452 7187 553 563
37. N. E. Sharpless INK4a/ARF: a multifunctional tumor suppressor locus Mutat. Res. 2005 576 1-2 22 38
38. L. Shayesteh et al., PIK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 1999 21 1 99 102
39. Y. Samuels et al., High frequency of mutations of the PIK3CA gene in human cancers Science 2004 304 5670 554
40. A. Sweet-Cordero et al., An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis Nat. Genet. 2005 37 1 48 55
41. J. O'Neil et al., Activating Notch1 mutations in mouse models of T-ALL Blood 2006 107 2 781 785
42. M. Kim et al., Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene Cell 2006 125 7 1269 1281
43. L. Zender et al., Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach Cell 2006 125 7 1253 1267
44. J. G. Hodgson et al., Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling Cancer Res. 2005 65 21 9695 9704
45. L. Chin et al., Making sense of cancer genomic data Genes Dev. 2011 25 6 534 555
46. J. S. Boehm W. C. Hahn Towards systematic functional characterization of cancer genomes Nat. Rev. Genet. 2011 12 7 487 498
47. H. W. Cheung et al., Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 2011 108 30 12372 12377
48. R. Brough et al., Functional Viability Profiles of Breast Cancer Cancer Discovery 2011 1 3 260 273
49. D. A. Barbie et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 2009 462 7269 108 112
50. J. Luo et al., A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 2009 137 5 835 848
51. A. Baldwin et al., Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3 Proc. Natl. Acad. Sci. U. S. A. 2010 107 28 12463 12468
52. A. Bommi-Reddy et al., Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen Proc. Natl. Acad. Sci. U. S. A. 2008 105 43 16484 16489
53. S. Bandyopadhyay et al., Rewiring of genetic networks in response to DNA damage Science 2010 330 6009 1385 1389
54. T. Horn et al., Mapping of signaling networks through synthetic genetic interaction analysis by RNAi Nat. Methods 2011 8 4 341 346
55. N. E. Sharpless R. A. Depinho The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug Discovery 2006 5 9 741 754
56. A. Akinc et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 2008 26 5 561 569
57. R. S. Maser et al., Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers Nature 2007 447 7147 966 971
58. J. Heyer et al., Non-germline genetically engineered mouse models for translational cancer research Nat. Rev. Cancer 2010 10 7 470 480
59. R. M. Bachoo et al., Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis Cancer Cell 2002 1 3 269 277
60. A. Bric et al., Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model Cancer Cell 2009 16 4 324 335
61. N. J. Abbott Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology Neurochem. Int. 2004 45 4 545 552
62. G. C. Chu et al., Stromal biology of pancreatic cancer J. Cell. Biochem. 2007 101 4 887 907
63. A. F. Hezel et al., Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev. 2006 20 10 1218 1249
64. J. A. Engelman J. Settleman Acquired resistance to tyrosine kinase inhibitors during cancer therapy Curr. Opin. Genet. Dev. 2008 18 1 73 79
65. Y. Matsumura H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986 46 12 Pt 1 6387 6392
66. H. Maeda et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000 65 1-2 271 284
67. R. A. Petros J. M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discovery 2010 9 8 615 627
68. C. P. Dillon et al., Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes Annu. Rev. Physiol. 2005 67 147 173
69. D. Reischl A. Zimmer Drug delivery of siRNA therapeutics: potentials and limits of nanosystems Nanomedicine 2009 5 1 8 20
70. G. J. Hannon J. J. Rossi Unlocking the potential of the human genome with RNA interference Nature 2004 431 7006 371 378
71. S. Akhtar I. F. Benter Nonviral delivery of synthetic siRNAs in vivo J. Clin. Invest. 2007 117 12 3623 3632
72. D. B. Rozema et al., Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc. Natl. Acad. Sci. U. S. A. 2007 104 32 12982 12987
73. J. D. Heidel et al., Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl. Acad. Sci. U. S. A. 2007 104 14 5715 5721
74. D. W. Bartlett et al., Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 2007 104 39 15549 15554
75. H. Lee et al., Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels J. Controlled Release 2007 119 2 245 252
76. W. J. Kim S. W. Kim Efficient siRNA delivery with non-viral polymeric vehicles Pharm. Res. 2009 26 3 657 666
77. D. Schaffert E. Wagner Gene therapy progress and prospects: synthetic polymer-based systems Gene Ther. 2008 15 16 1131 1138
78. P. Midoux et al., Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers Br. J. Pharmacol. 2009 157 2 166 178
79. M. S. Shim Y. J. Kwon Acid-responsive linear polyethylenimine for efficient, specific, and biocompatible siRNA delivery Bioconjugate Chem. 2009 20 3 488 499
80. A. J. Convertine et al., Development of a novel endosomolytic diblock copolymer for siRNA delivery J. Controlled Release 2009 133 3 221 229
81. S. Oliveira et al., Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes Int. J. Pharm. 2007 331 2 211 214
82. H. Hatakeyama et al., A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo J. Controlled Release 2009 139 2 127 132
83. A. Aigner Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs J. Biotechnol. 2006 124 1 12 25
84. D. D. Rao et al., Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development Cancer Gene Ther. 2009 16 11 807 809
85. D. D. Rao et al., siRNA vs. shRNA: similarities and differences Adv. Drug Delivery Rev. 2009 61 9 746 759
86. C. Wilson A. D. Keefe Building oligonucleotide therapeutics using non-natural chemistries Curr. Opin. Chem. Biol. 2006 10 6 607 614
87. D. De Paula et al., Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting RNA 2007 13 4 431 456
88. O. M. Merkel et al., Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance Mol. Pharm. 2009 6 4 1246 1260
89. O. M. Merkel et al., Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging J. Controlled Release 2009 138 2 148 159
90. L. Crombez et al., A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells Mol. Ther. 2009 17 1 95 103
91. L. Crombez et al., Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth Nucleic Acids Res. 2009 37 14 4559 4569
92. A. Eguchi et al., Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein Nat. Biotechnol. 2009 27 6 567 571
93. A. Malek et al., PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy J. Drug Targeting 2008 16 2 124 139
94. A. Zintchenko et al., Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity Bioconjugate Chem. 2008 19 7 1448 1455
95. M. S. Shim Y. J. Kwon Controlled delivery of plasmid DNA and siRNA to intracellular targets using ketalized polyethylenimine Biomacromolecules 2008 9 2 444 455
96. M. O. Andersen et al., RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications Methods Mol. Biol. (Totowa, N. J.) 2009 555 77 86
97. T. M. Sun et al., Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery Biomaterials 2008 29 32 4348 4355
98. N. Tietze et al., Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran Oligonucleotides 2008 18 2 161 174
99. J. Hoon Jeong et al., Reducible poly(amido ethylenimine) directed to enhance RNA interference Biomaterials 2007 28 10 1912 1917
100. D. Jere et al., Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells Biomaterials 2008 29 16 2535 2547
101. S. J. Tseng S. C. Tang Development of poly(amino ester glycol urethane)/siRNA polyplexes for gene silencing Bioconjugate Chem. 2007 18 5 1383 1390
102. S. C. Semple et al., Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 2010 28 2 172 176
103. K. T. Love et al., Lipid-like materials for low-dose, in vivo gene silencing Proc. Natl. Acad. Sci. U. S. A. 2010 107 5 1864 1869
104. S. A. Barros J. A. Gollob Toxicity profile of RNAi nanomedicines Adv. Drug Delivery Rev 2012
105. S. M. Lens et al., Shared and separate functions of polo-like kinases and aurora kinases in cancer Nat. Rev. Cancer 2010 10 12 825 841
106. D. Strumberg et al., Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors Int. J. Clin. Pharmacol. Ther. 2011 50 1 76 78
107. L. Huang Y. Liu In vivo delivery of RNAi with lipid-based nanoparticles Annu. Rev. Biomed. Eng. 2011 13 507 530
108. A. Schroeder et al., Lipid-based nanotherapeutics for siRNA delivery J. Intern. Med. 2010 267 1 9 21
109. M. M. Shahzad et al., Dual targeting of EphA2 and FAK in ovarian carcinoma Cancer Biol. Ther. 2009 8 11 1027 1034
110. M. J. Gray et al., Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver J. Natl. Cancer Inst. 2008 100 2 109 120
111. W. M. Merritt et al., Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth J. Natl. Cancer Inst. 2008 100 5 359 372
112. S. H. Kim et al., Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer J. Controlled Release 2008 129 2 107 116
113. N. Yagi et al., A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo Cancer Res. 2009 69 16 6531 6538
114. N. Toub et al., Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma Pharm. Res. 2006 23 5 892 900
115. O. Imamura et al., siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model Cancer Lett. (Shannon, Irel.) 2008 268 2 278 285
116. J. I. Cutler et al., Spherical nucleic acids J. Am. Chem. Soc. 2012 134 3 1376 1391
117. M. Oishi et al., Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing Chem. Lett. 2006 35 9 1046 1047
118. D. A. Giljohann et al., Gene regulation with polyvalent siRNA-nanoparticle conjugates J. Am. Chem. Soc. 2009 131 6 2072 2073
119. J. I. Cutler et al., Polyvalent nucleic acid nanostructures J. Am. Chem. Soc. 2011 133 24 9254 9257
120. P. C. Patel et al., Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles Bioconjugate Chem. 2010 21 12 2250 2256
121. D. S. Seferos et al., Polyvalent DNA nanoparticle conjugates stabilize nucleic acids Nano Lett. 2009 9 1 308 311
122. X. Q. Zhang et al., Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates ACS Nano 2009 5 9 6962 6970
123. Y. Song et al., Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging Angew. Chem., Int. Ed. 2009 48 48 9143 9147
124. J. S. Lee et al., Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery Nano Lett. 2009 9 6 2402 2406
125. G. B. Braun et al., Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates ACS Nano 2009 3 7 2007 2015
126. W. Lu et al., Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection Cancer Res. 2010 70 8 3177 3188
127. A. Elbakry et al., Layer-by-layer assembled gold nanoparticles for siRNA delivery Nano Lett. 2009 9 5 2059 2064
128. S. Guo et al., Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte ACS Nano 2010 4 9 5505 5511
129. W. J. Song et al., Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery Small 2009 6 2 239 246
130. S. Kirkland-York et al., Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers Biomacromolecules 2010 11 4 1052 1059
131. S. H. Lee et al., Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers Int. J. Pharm. 2008 364 1 94 101
132. A. C. Bonoiu et al., Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons Proc. Natl. Acad. Sci. U. S. A. 2009 106 14 5546 5550
133. M. E. Davis et al., Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 2008 7 9 771 782
134. S. Hirsjarvi et al., Passive and active tumour targeting with nanocarriers Curr. Drug Discovery Technol. 2011 8 3 188 196
135. T. Yoshizawa et al., Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts Eur. J. Pharm. Biopharm. 2008 70 3 718 725
136. M. E. Davis et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 2010 464 7291 1067 1070
137. E. Song et al., RNA interference targeting Fas protects mice from fulminant hepatitis Nat. Med. (N. Y.) 2003 9 3 347 351
138. H. P. Vornlocher Antibody-directed cell-type-specific delivery of siRNA Trends Mol. Med. 2006 12 1 1 3
139. E. Song et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 2005 23 6 709 717
140. P. Kumar et al., Transvascular delivery of small interfering RNA to the central nervous system Nature 2007 448 7149 39 43
141. R. M. Schiffelers et al., Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 2004 32 19 e149
142. J. O. McNamara, 2nd et al., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 2006 24 8 1005 1015
143. O. C. Farokhzad R. Langer Impact of nanotechnology on drug delivery ACS Nano 2009 3 1 16 20
144. J. E. Dancey et al., The genetic basis for cancer treatment decisions Cell 2012 148 3 409 420
145. A. D. Cox C. J. Der The RAF inhibitor paradox revisited Cancer Cell 2012 21 2 147 149
146. A. T. Weeraratna RAF around the edges - the paradox of BRAF inhibitors N. Engl. J. Med. 2011 366 3 271 273
147. I. I. Wistuba et al., Methodological and practical challenges for personalized cancer therapies Nat. Rev. Clin. Oncol. 2011 8 3 135 141
148. R. Straussman et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012
149. Z. Chen et al., A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 2012 483 7391 613 617